Press Release
October 1, 2025
A Biotech Breakthrough for Hair Integrity
Kaiseraugst (Switzerland), Maastricht (Netherlands), October 1st 2025
dsm-firmenich, innovators in nutrition, health, and beauty, is proud to introduce patent-pending Bond Aid, a next-generation ingredient solution powered by OXY 229 CB—a biotech-derived innovation designed to visibly restore hair integrity and vitality.
As consumers increasingly seek high-performance solutions that address daily hair damage from heat styling, coloring, ultraviolet ray exposure, and environmental stressors, Bond Aid responds with a new scientific breakthrough.
“Hair is under constant attack from everything your body is exposed to—sun, pollution, diet, sleep, and stress.” says Fabrice Guillemard, Director of Marketing for Beauty & Care at dsm-firmenich. “With Bond Aid, we’re addressing hair repair in a more holistic, science-backed way—leveraging biotechnology and peptide innovation to meet real-world consumer needs.”
A New Era of Hair Wellness: Biotech Powers Bond Aid
Bond Aid unites three high-impact trends in one advanced formulation:
Designed for seamless integration, Bond Aid with OXY 229 CB delivers high performance at just 1% concentration, making it ideal for both leave-on and rinse-off hair care formulations. Bond Aid exemplifies a modern approach to effective and eco-conscious hair repair with visible transformation from the first use.
Scientifically Tested. Naturally Sourced. Performance You Can Feel.
To efficiently assess the structural and functional characteristics of the comprehensive array of peptides in OXY 229 CB, numbering more than 700, molecular modelling was performed on a representative subset of 19 peptides for their binding interactions with keratin, the key protein within hair. These molecular simulations revealed a novel ability to target hair fibers on interior levels, enabling multi-dimensional structural repair.
Key performance indicators include:
Bond Aid with OXY 229 CB aligns with the principles of clean beauty while supporting sensory appeal and hair health. Derived from a natural and sustainable yeast extract, OXY 229 CB is a biotech ingredient made from baker’s yeast with rapeseed-derived glycerin and is 98.17% natural-origin (ISO 16128). dsm-firmenich maintains full supply-chain control, without the use no palm-oil derivatives, and the material is Halal-certified (Halal Food Council of Europe). Its profile shows a carbon footprint of 0.55 kg CO₂-eq/kg, water footprint of 0.65, and it is readily biodegradable (OECD tests), with footprints calculated via internal LCA to ISO 14040/44. The ingredient also aligns with UN SDG 3: Good Health & Well-Being, pairing sustainability with benefits to hair integrity and skin vitality.
About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people.
LinkedIn | X | Instagram | Facebook
For more information
Global Marketing Communications Beauty & Care
tel. +41 618158888
dsm-firmenich beautycare.communications@dsm-firmenich.com
Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich’s future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.